Ibrutinib Treatment Shows Efficacy and Tolerability in Heavily Treated CLL Patients Following Allogeneic Stem Cell Transplant

Ibrutinib Treatment Shows Efficacy and Tolerability in Heavily Treated CLL Patients Following Allogeneic Stem Cell Transplant

You have to admire Pharmacyclics advertising capability. Here they are showing how effective Ibrutinib (Imbruvica) is on a tough to treat bunch of CLL patients. "These patients had a median of five prior therapies and 63% were high-risk del 17p CLL patients. The estimated median progression-free survival (PFS) at 24 months was 76.6%. All patients had previously undergone allogeneic stem cell transplants."

pipelinereview.com/index.ph...

Neil

Photo: Some red eucalyptus blossoms

2 Replies

oldestnewest
  • It's nice to know there is still options after such a hellish road. Thank you. I needed that after that previous post about hospice. Keep the GOOD news coming.

    Jeff

  • Read Brian Koffman's blog some time, in particular the early entries:

    bkoffman.blogspot.com.au/

You may also like...